The application draws on data from the FULCRUM-VT pivotal IDE trial, which enrolled 209 patients across 20 centres.

Adagio Medical (Nasdaq:ADGM) announced today that it submitted its premarket approval (PMA) application to the FDA for its ...

Please provide your email address to receive an email when new articles are posted on . Patients with scar-related ventricular tachycardia (VT) who received VT ablation plus a subcutaneous ICD had ...

NEW ORLEANS – The Impella 5.0 and 5.5 left ventricular assist device failed to measure up on outcomes when used for high-risk patients undergoing ventricular tachycardia (VT) ablation therapies, ...

Directing patients selectively to centers performing higher volumes of ventricular tachycardia (VT) ablation may help reduce in-hospital complications following the procedure, an observational study ...

Ablation, a procedure to treat abnormal electrical short circuits caused by a heart attack and is usually reserved for patients who do not improve with medication, may be a better first-line treatment ...

"FULCRUM-VT represents a seminal step forward in advancing ventricular tachycardia management by delivering positive, clinically meaningful results from the first large-scale, rigorously executed ...

LAGUNA HILLS, Calif., March 19, 2026--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment ...

Direct oral anticoagulants (DOACs) bested aspirin for cerebrovascular prevention after left ventricular (LV) arrhythmia ablation, the STROKE-VT trial showed. The anticoagulants eliminated stroke ...

Ventricular tachycardia is a life-threatening heart condition. It occurs when the electrical impulses controlling the heartbeat become erratic, causing the heart to beat too quickly. When this happens ...